FDA links some prostate drugs to cancer risk

June 9, 2011

(AP) -- The Food and Drug Administration expanded the warning label on a group of prostate drugs Thursday, saying they may increase the risk of a more serious form of prostate cancer.

The FDA is updating the warning information on a group of drugs including PLC's Avodart and & Co.'s Proscar, which are used to shrink the prostate. The warning indicates the drugs are linked to a greater risk of high-grade prostate cancers. While the drugs have been shown to reduce the risk of overall, the FDA said the drugs were linked to an increased risk of more serious cancers.

Earlier this year, Merck, based in Whitehouse Station, N.J., and British drugmaker GlaxoSmithKline asked the FDA to approve the drugs as preventive treatments for prostate cancer, but the agency refused, citing the risk of high-grade cancer. In March, GlaxoSmithKline said it was abandoning global efforts to get Avodart approved as a preventive cancer drug.

The agency is basing its conclusions on a review of two studies in which about 27,000 men 50 and older used the drugs for several years. The FDA said the risk of high-grade prostate cancers is small, but doctors should be aware of it.

The drugs are also known as dutasteride and finasteride, respectively. Finasteride is also available as a low-cost generic.

Explore further: Generic prostate drug helps find high-risk cancers early

0 shares

Related Stories

Generic prostate drug helps find high-risk cancers early

September 11, 2007

Men now have another good reason to consider taking finasteride, a well-known generic drug that shrinks an enlarged prostate and reduces the risk of getting prostate cancer by 25 percent. A new study from the Southwest Oncology ...

Study finds possible heart risk with prostate drug

March 31, 2010

(AP) -- Full results of a big study testing a drug for preventing prostate cancer show a higher risk of heart failure, a surprise finding that could dampen enthusiasm for expanding its use.

FDA reviews 2 new drugs to reduce prostate cancer

November 29, 2010

(AP) -- Health regulators said Monday that two drugs from GlaxoSmithKline and Merck reduce the risk of prostate cancer in men, though scientists questioned the drugs' overall benefit, since the tumors they prevent are usually ...

Drug may slow growth of early prostate cancer

February 15, 2011

A new study suggests a way to help men with early, low-risk prostate cancer avoid being overtreated for a disease that in most cases will never threaten their lives. It found that a drug can slow the growth of these tumors ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.